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The Short Form-12 Health Survey (SF-12) is used to assess the patient’s quality of life (QoL) using the physical
component score (PCS) and the mental component score (MCS). The purpose of this study was to determine
whether the SF-12 PCS and MCS are associated with psoriasis severity and to compare QoL between Murdough
Family Center for Psoriasis (MFCP) patients and patients with other major chronic diseases included in the
National Survey of Functional Health Status data. We used data from 429 adult patients enrolled in MFCP.
Psoriasis Area Severity Index (PASI) was used to assess psoriasis severity at the time of completion of the SF-12
questionnaire. Other variables included age, sex, body mass index, psoriatic arthritis, psychiatric disorders,
and comorbidities. Linear regression models were used to estimate effect sizes ±95% confidence intervals.
For every 10-point increase in PASI, there was a 1.1±1.3 unit decrease in MCS (P¼ 0.100) and a 2.4±1.3 unit
decrease in PCS (Po0.001). Psoriasis severity was associated with PCS and MCS after adjusting for variables,
although the strength of the relationship was attenuated in some models. Psoriasis severity is associated with
decreased QoL. SF-12 may be a useful tool for assessing QoL among psoriasis patients.
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INTRODUCTION
Numerous studies have demonstrated the significant negative
impact that psoriasis has on quality of life (QoL; Finlay
and Coles, 1995; Fleischer et al., 1996; De Arruda and
De Moares, 2001; Krueger et al., 2001; Zachariae et al.,
2002). Furthermore, as a chronic disease, psoriasis affects the
QoL of both patients and their close relatives in a cumulative
way (Tadros et al., 2011). Various factors may contribute to
the lower QoL in psoriasis patients. The chronic nature of the
disease and the lack of control over unexpected outbreaks of
the symptoms are among the most bothersome aspects of
psoriasis (Gelfand et al., 2004). Patients may feel humiliated
when they need to expose their bodies during swimming,
intimate relationships, using public showers, or living in
conditions that do not provide adequate privacy (Fortune
et al., 2005). Psoriasis affects patients’ social life, daily
activities, occupational, and sexual functioning (Weiss et al.,
2002). People suffering from psoriasis feel that the general
public and sometimes their own physicians fail to appreciate
the negative impact of psoriasis on their life (Stern et al.,
2004). Treatment of psoriasis, as it may add a substantial
financial burden to patients and may be associated with risks
for adverse effects, is also an important component of the
QoL of psoriasis patients (Feldman et al., 1997). Although the
impact of psoriasis on QoL may decrease over time regardless
of the treatment of the disease (Unaeze et al., 2006),
improving the QoL of psoriasis patients is a desirable and
attainable goal. Therefore, the interventions to improve the
process of care for this population often assess QoL outcomes
such as social functioning, overall health status, and
emotional well-being. These outcomes may be affected by
coexisting chronic conditions and it is therefore important to
adjust for these effects.
Various measures have been used to assess QoL in
psoriasis patients, each of them emphasizing a different
aspect of the disease that may or may not incorporate the
impact of psoriasis comorbidities (Bronsard et al., 2010).
Usually, generic measures are used to compare outcomes
across different populations and interventions, particularly
for cost-effectiveness studies. Disease-specific measures
assess the special states and concerns of diagnostic groups.
Specific measures may be more sensitive for the detection
and quantification of small changes that are important to
clinicians or patients (Patrick and Deyo, 1989). By utilizing
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the Short Form-36 (SF-36), a generic QoL instrument, it has
been demonstrated that psoriasis may cause as much
disability as other major medical diseases, including cancer,
arthritis, hypertension, heart disease, diabetes, and depres-
sion (Rapp et al., 1999).
We sought to determine whether the Short Form-12
(SF-12), a shorter, yet valid alternative to the SF-36 (Ware
et al., 2002), whose 12 questions are all selected from the
SF-36, might be useful in assessing the QoL of psoriasis
patients. The purpose of this study was to determine whether
the SF-12 physical component score (PCS) and mental
component score (MCS) are associated with psoriasis severity
and to compare QoL between Murdough Family Center for
Psoriasis (MFCP) patients and patients with other major
chronic diseases included in the National Survey of Func-
tional Health Status (NSFHS) data.
RESULTS
Descriptive analysis
Summary of the descriptive statistics for variables of interest is
shown in Table 1.
The mean values of SF-12 scores for the present sample
were compared with the mean values from the 1998 National
Survey of Functional Health Status data (Ware et al., 2002). A
qualitative comparison of the scores revealed that psoriasis
patients had MCSs that were similar to those of patients
with heart disease, chronic allergies, hearing impairment,
osteoarthritis, back pain or sciatica, dermatitis, diabetes,
rheumatoid arthritis, and cancer, whereas they had PCSs that
were similar to those of patients with back pain or sciatica,
dermatitis, depression, anemia, and vision or hearing impair-
ment (Table 2).
Unadjusted associations of variables with SF-12
Unadjusted associations of variables with SF-12 are shown in
Table 3.
On average, older subjects felt worse physically but better
mentally. Men reported higher PCS and MCS compared with
women. Increased body mass index was associated with
decreased physical health component, whereas it was not
associated with mental health component. It was evident that
Psoriasis Area Severity Index (PASI) was associated with low
mental health, although the P-value did not show statistical
significance: for every 10-point increase in PASI, there was an
associated 1.1±1.3 unit decrease in MCS (P¼0.100). PASI
was associated with low physical health: for every 10-point
increase in PASI, there was an associated 2.4±1.3 unit
decrease in PCS (Po0.001). On average, subjects who had
psoriatic arthritis (PsA) reported worse physical well-being
but not worse mental well-being. Psychiatric conditions and
other comorbidities were associated with decreased QoL: for
Table 1. Summary statistics for variables of interest in
the sample of chronic plaque psoriasis patient
Continuous variables
Available
sample size Mean SD
Age (years) 429 48.7 15.4
BMI (kgm2) 429 30.4 7.5
PASI 429 8.0 9.2
Comorbidities (number) 429 2.1 1.8
PCS 429 45.6 12.5
MCS 429 47.5 12.2
DLQI 162 8.7 7.0
Categorical variables Number Available
sample size
Percent
Males 231 429 54%
Psoriatic arthritis 111 425 26%
Psychiatric disorder 142 429 33%
Abbreviations: BMI, body mass index, calculated by the ratio between
weight in kilograms and the square of height in meters; DLQI,
Dermatology Life Quality Index; MCS, mental component score; PASI,
Psoriasis Area Severity Index; PCS, physical component score.
Table 2. Mental and physical component scores of
psoriasis patients compared with general US
populations, including healthy adults and those with
chronic diseases
MCS PCS
Mean (SD) Rank Mean (SD) Rank
Healthy adults 52.3 (7.9) 1 54.3 (6.2) 1
General US population 49.4 (9.8) 2 49.6 (9.9) 2
Hypertension 49.1 (9.5) 3 43.7 (10.3) 10
Chronic allergies 48.6 (10.0) 4 49.4 (10.0) 3
Heart disease 48.3 (10.1) 5 38.8 (10.0) 17
Hearing impairment 48.0 (9.9) 6 44.7 (10.4) 9
Psoriasis (MFCP database) 47.5 (12.2) 7 45.6 (12.5) 6
Osteoarthritis/degenerative
arthritis
47.5 (10.2) 7 38.9 (10.1) 16
Back pain or sciatica 47.4 (10.5) 8 46.0 (11.0) 5
Dermatitis 47.3 (10.5) 9 47.8 (10.8) 4
Diabetes 47.3 (10.7) 9 41.5 (11.1) 13
Rheumatoid arthritis 47.2 (10.3) 10 40.6 (10.5) 15
Cancer (except skin cancer) 47.1 (10.1) 11 40.8 (10.0) 14
Vision impairment 45.7 (11.2) 12 44.1 (11.2) 8
Lung disease 45.6 (10.7) 13 38.3 (10.5) 18
Kidney disease 45.2 (10.1) 14 37.9 (11.2) 19
Ulcer or stomach disease 45.1 (11.3) 15 43.2 (11.6) 11
Anemia 44.8 (11.00) 16 45.5 (11.9) 7
Liver disease 44.1 (12.9) 17 42.0 (12.1) 12
Depression 37.4 (10.8) 18 45.6 (11.7) 6
Abbreviations: MCS, mental component score; MFCP, Murdough Family
Center for Psoriasis; PCS, physical component score.
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each additional comorbidity, there was an associated
3.40±0.57 unit decrease in PCS (Po0.001) and an
associated 0.48±0.64 unit decrease in MCS (P¼0.138).
Worse QoL measured by Dermatology Life Quality Index
(DLQI) was associated with worse overall QoL measured by
SF-12 physical and MCSs.
Adjusted associations of PASI with SF-12
Adjusted associations of PASI with SF-12 MCS. After
adjusting for age, gender, and body mass index, the effect
of PASI on MCS was found to be statistically significant
(P¼0.017). Additional adjustment for PsA, psychiatric
disorders, or comorbidities did not change this result. The
observed size of the effect of PASI on MCS was similar for the
set of models considered (Table 4).
Adjusted associations of PASI with SF-12 PCS. For the
outcome of PCS, adjusting for age, gender, and body mass
index did not change the association of PASI with PCS
(Table 4). Adjusting additionally for psychiatric disorders also
did not change the relationship very much. However, PsA and
comorbidities were confounders accounting for the greatest
decrease of the association of PASI with PCS (Table 4).
Association of DLQI with SF-12
We found a statistically significant association of DLQI with
SF-12: for every unit increase in DLQI, there was an
associated 0.50±0.24 unit decrease in the physical compo-
nent of SF-12 (Po0.001), as well as an associated 0.53±0.25
unit decrease in the mental component of SF-12 (Po0.001;
Table 3). Although statistically significant, this association
was weak (correlation coefficient of 0.33 for DLQI versus
MCS, and correlation coefficient of 0.31 for DLQI versus
PCS; Figures 1 and 2).
DISCUSSION
This study extends research on the impact of psoriasis on QoL
by introducing the SF-12 tool. Previously, the SF-12 has been
used in dermatology to assess health values (utilities) from the
general public for health states common to people with PsA and
scleroderma for economic evaluations (Khanna et al., 2010).
We have used the SF-12 to assess the physical and mental
components of QoL of patients with chronic plaque psoriasis.
Comparative impact of psoriasis on QoL
As a generic QoL measure, the SF-12 provides an opportunity
to compare the impact of psoriasis on QoL with the impact of
Table 3. Unadjusted associations of variables with SF-12
MCS PCS
N Effect1 (CI) P-value Effect1 (CI) P-value
Age (years) 429 0.13 (0.06, 0.21) o0.001 0.23 (0.31, 0.16) o0.001
Gender (males) 429 3.14 (0.84, 5.45) 0.008 3.08 (0.71, 5.44) 0.011
BMI (kgm2) 429 0.10 (0.05, 0.25) 0.206 0.47 (0.63, 0.32) o0.001
PASI (10-point change) 429 1.1 (2.3, 0.2) 0.100 2.4 (3.7, 1.1) o0.001
PsA 425 0.04 (2.60, 2.69) 0.976 6.86 (9.49, 4.23) o0.001
Psychiatric disorder 429 9.16 (11.46, 6.86) o0.001 4.10 (6.59, 1.61) 0.001
Comorbidites (number) 429 0.48 (1.12, 0.16) 0.138 3.40 (3.97, 2.83) o0.001
DLQI 162 0.53 (0.78, 0.29) o0.001 0.50 (0.74, 0.26) o0.001
Abbreviations: BMI, body mass index, calculated by the ratio between weight in kilograms and the square of height in meters; CI, confidence interval;
DLQI, Dermatology Life Quality Index; MCS, mental component score; PCS, physical component score; PsA, psoriatic arthritis; SF-12, the Short Form-12
Health Survey.
1Effect indicates the estimated average change in MCS or PCS associated with a unit change in the covariate.




PASI change (CI) P-value
Effect of 10-point
PASI change (CI) P-value
None 429 1.1 (2.3, 0.2) 0.100 2.4 (3.7, 1.1) o0.001
Age+gender+BMI 429 1.5 (2.8, 0.3) 0.017 2.1 (3.3, 0.9) o0.001
Age+gender+BMI+PsA 425 1.5 (2.8, 0.2) 0.025 1.5 (2.8, 0.3) 0.015
Age+gender+BMI+psychiatric disorder 429 1.0 (2.2, 0.2) 0.097 1.9 (3.1, 0.7) 0.002
Age+gender+BMI+comorbidity 429 1.3 (2.6, 0.1) 0.038 1.6 (2.8, 0.5) 0.004
Abbreviations: BMI, body mass index, calculated by the ratio between weight in kilograms and the square of height in meters; CI, confidence interval; MCS,
mental component score; PASI, Psoriasis Area Severity Index; PCS, physical component score; PsA, psoriatic arthritis; SF-12, the Short Form-12 Health Survey.
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other chronic conditions, as well as with the QoL of a normal
population. Our results confirm that psoriasis has a negative
impact on QoL, outlining its place among 18 other chronic
medical conditions (Table 2). These findings are consistent
with a previous study that used SF-36 and compared it with
1990 National Survey of Functional Health Status data (Rapp
et al., 1999). In that study, it was demonstrated that the mean
values of MCSs for patients with psoriasis were lower than
those for patients with heart disease, diabetes, and cancer.
Regarding the PCSs, only patients with congestive heart
failure had lower scores than psoriasis patients. However, it
should be noted that 51% of the patients with psoriasis in that
study had arthritis (type undefined) as compared with 26% of
our patients having PsA. Although our SF-12 physical and
MCS results did not place psoriasis among the lowest groups
of chronic medical conditions, our results did show that
psoriasis had a negative impact on QoL comparable to the
impact of other major medical and psychiatric diseases.
Impact of psoriasis severity on the mental and physical
component of QoL
Because psoriasis severity is associated with MCS, perhaps
patients with psoriasis need to have the severity of their
disease addressed not only by the more traditional physical
measures but also by determining the impact of the disease
on patients’ mental functioning.
PsA and other comorbidities were potential confounders,
revealing a smaller effect of PASI on PCS than it was
suggested without adjusting for them; hence, the SF-12 results
should be interpreted with caution in psoriasis patients as
psoriasis is commonly associated with PsA and with other
comorbidities. Our findings support the concept that psoriasis
severity should include both physical and psychosocial
measures of severity (Nichol et al., 1996; Kirby et al., 2001;
Bhosle et al., 2006). Measures such as PASI, which include
only a physical component, might be reinforced by a more
global assessment of psoriasis disease severity. It is appro-
priate to include QoL assessment in the treatment decision-
making process as well (Feldman et al., 2005).
We confirm previously reported results that age is
negatively associated with measures of physical functioning
but is positively correlated with mental functioning scores
(Stern et al., 2004; Jankovic et al., 2011): older patients feel
physically worse, but mentally better. This finding is
intriguing as medical comorbidities and functional deficits
typically increase with age, leading to limited physical
abilities in the elderly.
Association of DLQI and SF-12
It has been previously demonstrated that capturing patient-
reported outcomes is important in clinical trials of moderate-
to-severe plaque psoriasis (Shikiar et al., 2006). Although the
DLQI provides the most reliable measure of clinical change,
the SF-36 and the EuroQOL-5D (EQ-5D) generic tools
performed well as general measures of health status out-
comes (Tadros et al., 2011). The DLQI is useful as a QoL
measure in skin-specific settings and our study shows the
SF-12 to be useful as well. The existence of patients with
poor PCS/MCS and good DLQI is what we would expect to
see given the weak correlation between these two tools.
However, as the DLQI and the SF-12 are not highly
correlated, we believe that these two tools measure different
aspects of QoL. We therefore suggest that it may be prudent
to use two different tools to assess QoL among psoriasis
patients (for example, the DLQI or another skin-specific
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Figure 1. Associations of DLQI with SF-12. Plot of the association between
DLQI and MCS (correlation coefficient 0.33). DLQI, Dermatology Life
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Figure 2. Associations of DLQI with SF-12. Plot of the association between
DLQI and PCS (correlation coefficient 0.31). DLQI, Dermatology Life
Quality Index; PCS, physical component score; SF-12, the Short Form-12
Health Survey.
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Strengths and limitations
A potential limitation of the study is the use of a convenience
rather than a random sample. The specific contribution of this
work is that we show the advantage of the SF-12 over the
widely used generic SF-36 because it is shorter, takes less
time to be filled out than the SF-36, and gives information as
valid as that of the SF-36.
Conclusions
Psoriasis has a negative impact on the patient’s QoL, similar
to the impact of other major chronic diseases. The impact of
the disease on the mental and physical functions of patients is
greater in those with more severe disease. Presence of PsA,
psychiatric disorders, and other comorbidities should be
taken into account when assessing the impact of psoriasis
severity on patients’ QoL. The SF-12 may be a useful tool for
assessing QoL among psoriasis patients, along with disease-
specific tools such as DLQI.
MATERIALS AND METHODS
Sample
The data were derived from the MFCP database, a questionnaire-
based survey approved by the Institutional Review Board of
University Hospitals, Cleveland. Any patient of any age with chronic
plaque psoriasis was eligible to enter the database. All patients were
derived either from routine dermatology clinics at the University
Hospitals Case Medical Center or from community-based dermatol-
ogy practices in northeast Ohio. The MFCP database questionnaire
has five distinct sections, including general information, personal
psoriasis and medical history, family medical history, health-related
QoL self-reported measurements such as SF-12 and DLQI, and data
derived from physical examination including PASI, body surface
area, blood pressure, height, and weight. A total of 429 chronic
plaque psoriasis patients have completed the MFCP database
questionnaire since its inception in 2007.
Measures
Original Short Form-12 Health Survey (SF-12). The SF-12, a
compact 12-item one-page self-reported questionnaire, provides
easily interpretable scales for physical and mental health. All ‘‘SF’’
forms measure the same eight domains of health: physical
functioning, role functioning related to physical status, body pain,
general health, vitality, social functioning, role functioning related
to emotional status, and mental health. The eight dimensions of
the SF-12 can be combined into two summary scores, the PCS
and the MCS. PCS and MCS range from 0 to 100, where zero
indicates the lowest level of health and 100 indicates the highest
level of health. Both PCS and MCS are scored in such a way that they
compare to a national norm with a mean score of 50.0 and a
standard deviation of 10.0. The SF-12 has been developed, tested,
and validated by Quality Metric Incorporated (Ware et al., 2002).
Dermatology Life Quality Index (DLQI). The DLQI is a skin-
specific compact self-reported questionnaire to measure QoL over
the previous week in patients with skin diseases. It consists of 10
items covering symptoms and feelings, daily activities, leisure,
work and school, personal relationships, and treatment. Each item
is scored on a four-point scale with scores ranging from 0 to 30,
with lower scores indicating higher levels of QoL (Finlay and
Khan, 1994).
Psoriasis severity. Psoriasis disease severity was assessed using the
PASI measured at the time of completion of the SF-12 questionnaire.
Outcomes and variables
Our hypothesis was that QoL would be worse for patients with the
most severe form of psoriasis and would be better for those with
milder psoriasis and that the SF-12 would be able to measure these
differences. Variables that we adjusted for included age, gender,
and body mass index. We also adjusted for the following: evidence
of PsA, which was defined by self-reported diagnosis of PsA and
confirmed by a rheumatologist; the presence of psychiatric disorders,
which was defined by a self-reported diagnosis of depression,
anxiety, or obsessive compulsive disorder, which was confirmed
either by a psychiatrist or by the use of psychiatric medications
(including antidepressant or antianxiety agents); and for the number
of medical comorbidities, which was defined by the Charlson
comorbidity index, a validated index to measure the burden of
comorbidity calculable from the self-reported data in the MFCP
database (Charlson et al., 1987; Katz et al., 1996).
Statistical analysis
Simple and multivariable linear regression models were used to
estimate effect sizes and their 95% confidence intervals.
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